Search research articles
Contact Us
Filters
Showing results (41-50 of 182) with videos related to
Page
of 19
Sort By:
Genes, Chromosomes & Cancer
|
April 3, 2008
High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss
Matthew H Kulke, Ellen Freed, Derek Y Chiang, et al.
Cancer Investigation
|
June 17, 2006
A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma
Matthew H Kulke, Alona Muzikansky, Jeffrey Clark, et al.
Journal of Gastrointestinal Cancer
|
August 20, 2018
Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database
Maxine D Fisher, Sonia Pulgar, Matthew H Kulke, et al.
The Oncologist
|
January 31, 2020
Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center
Jessica J Jalbert, Roman Casciano, Jie Meng, et al.
Pancreas
|
July 29, 2010
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas
Jonathan R Strosberg, Domenico Coppola, David S Klimstra, et al.
Oncotarget
|
September 15, 2017
Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma
Michaela Bowden, Chensheng W Zhou, Sui Zhang, et al.
Cancer Investigation
|
July 1, 2006
A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus
Matthew H Kulke, Bingyan Wu, Jeffrey W Clark, et al.
Cancer Investigation
|
October 21, 2004
A phase II study of docetaxel in patients with metastatic carcinoid tumors
Matthew H Kulke, Haesook Kim, Keith Stuart, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 14, 2011
Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus
James C Yao, Marianne Pavel, Alexandria T Phan, et al.
The Oncologist
|
August 7, 2014
Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study
Jonathan R Strosberg, Al B Benson, Lynn Huynh, et al.
Page
of 19
Search research articles
Search
Showing results (41-50 of 182) with videos related to
Sort By:
Page
of 19
Genes, Chromosomes & Cancer
|
April 3, 2008
High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss
Matthew H Kulke, Ellen Freed, Derek Y Chiang, et al.
Cancer Investigation
|
June 17, 2006
A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma
Matthew H Kulke, Alona Muzikansky, Jeffrey Clark, et al.
Journal of Gastrointestinal Cancer
|
August 20, 2018
Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database
Maxine D Fisher, Sonia Pulgar, Matthew H Kulke, et al.
The Oncologist
|
January 31, 2020
Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center
Jessica J Jalbert, Roman Casciano, Jie Meng, et al.
Pancreas
|
July 29, 2010
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas
Jonathan R Strosberg, Domenico Coppola, David S Klimstra, et al.
Oncotarget
|
September 15, 2017
Profiling of metastatic small intestine neuroendocrine tumors reveals characteristic miRNAs detectable in plasma
Michaela Bowden, Chensheng W Zhou, Sui Zhang, et al.
Cancer Investigation
|
July 1, 2006
A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus
Matthew H Kulke, Bingyan Wu, Jeffrey W Clark, et al.
Cancer Investigation
|
October 21, 2004
A phase II study of docetaxel in patients with metastatic carcinoid tumors
Matthew H Kulke, Haesook Kim, Keith Stuart, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 14, 2011
Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus
James C Yao, Marianne Pavel, Alexandria T Phan, et al.
The Oncologist
|
August 7, 2014
Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study
Jonathan R Strosberg, Al B Benson, Lynn Huynh, et al.
Page
of 19